TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Patients who completed 6-week short-term treatment study for Major Depressive Episode (MDE), NCT00839423 / 11492A, followed by a 2-week taper period~Exclusion Criteria:~* Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV TR)~* Female patients of childbearing potential who are not using effective contraception~* Use of any psychoactive medication~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for HIV-1 uninfected partner:~* Partner within an HIV-1 discordant heterosexual relationship~* One partner meets study eligibility for HIV-1 uninfected study participant and the other partner meets study eligibility criteria for HIV-1 infected participant~* Plan to remain in the relationship for the duration of the study period~* Adequate renal, hepatic \& hematologic function~* Negative Hepatitis B surface antigen test~* Willing and able to provide written informed consent \& locator information~Exclusion Criteria for HIV-1 uninfected partner:~* Current pregnancy, or planning to become pregnant during the study period~* Currently breastfeeding~* Concurrent enrollment in another HIV-1 vaccine or prevention trial~* Receiving ongoing antiretroviral therapy~* Repeated positive urine dipstick tests for glycosuria or proteinuria~* Active and serious infections~* History of pathological bone fractures not related to trauma~Inclusion Criteria for HIV-1 infected partner:~* Partner within an HIV-1 discordant heterosexual relationship~* One partner meets study eligibility for HIV-1 uninfected study participant and the other partner meets study eligibility criteria for HIV-1 infected participant~* HIV-1 infected based on positive EIA~* No history of any clinical AIDS-defining diagnoses~* Plan to remain in the relationship for the duration of the study period~* Willing and able to provide written informed consent \& locator information~Exclusion Criteria for HIV-1 infected partner:~* Current use of antiretroviral therapy~* Concurrent enrollment in another HIV-1 treatment trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Tenofovir Disoproxil Fumarate (TDF) (Type: ACTIVE_COMPARATOR): TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
- Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) (Type: ACTIVE_COMPARATOR): FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo TDF + Placebo FTC/TDF orally, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals between 6-17 years of age and 51 years of age or older~* Individuals who were in good health~* Provided consent, complied with study procedures and duration of follow-up~Exclusion Criteria:~* Contraindications to vaccination with rabies vaccine~* Body temperature ≥37.5◦C (axillary) within 3 days of intended study vaccination~* Known hypersensitivity to the components of the vaccine~* Previously received any rabies vaccine or immune globulin~* Previous or planned treatment with antimalarial medications~* History of psychiatric disease, immune disorder, bleeding disorder, drug/alcohol abuse within the past 2 years, malignancy~* Female subjects who were pregnant or unwilling to practice acceptable birth control methods~* Individuals enrolled or plans to enroll in another investigational trial

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zagreb(≥6 to ≤17 Years) (Type: EXPERIMENTAL): None
- Zagreb(≥51 Years) (Type: EXPERIMENTAL): None
- Essen(≥6 to ≤17 Years) (Type: ACTIVE_COMPARATOR): None
- Essen(≥51 Years) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. histologically or cytologically confirmed diagnosis of any advanced or metastatic relapsed or refractory solid tumor.~Exclusion criteria:~1. Active brain metastases~2. Patients with known pre-existing interstitial lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib and docetaxel (Type: None): None
- Afatinib and gemcitabine (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
The trial entry criteria are based on:~1. A diagnosis of definite NAFLD on liver biopsy obtained within 3 months of screening.~2. ≥20 years of age at the time of the initial screening.~3. Patients with type 2 diabetes mellitus at the time of screening need to have glycemic control (HbA1c of ≥7%) and have been managed by either diet and/or a stable dose of hypoglycemic agents for at least 4 weeks.~Exclusion Criteria~1. Hepatic virus infections (hepatitis B and C, cytomegalovirus, and Epstein-Barr virus), autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, hemochromatosis, alpha 1-antitrypsin deficiency, Wilson's disease, history of parenteral nutrition.~2. Use of agents known to induce steatosis (e.g., valproate, amiodarone, or vitamin E)~3. Hepatic injury caused by substance abuse.~4. Current consumption of more than 20 g of alcohol daily.~5. Hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding~6. Elevated serum bilirubin level of more than two-fold the upper normal limit.~7. Tofogliflozin or glimepiride hypersensitivity or contraindications.~8. History of type 1 diabetes.~9. History of ketoacidosis.~10. History of symptoms of severe hypoglycemia.~11. Treatment with SGLT2 inhibitor including tofogliflozin within 4 weeks of screening.~12. Treatment with glinide and sulfonylurea use within 4 weeks of screening.~13. Concomitant corticosteroid therapy uses within 4 weeks of screening.~14. Poorly controlled unstable diabetes (ketoacidosis or an increase in HbA1c of \>3% in the 12 weeks before screening).~15. Poorly controlled hypertension or systolic blood pressure of \>160 mmHg or diastolic blood pressure of \>100 mmHg.~16. Artificial dialysis or moderate renal dysfunction.~17. Poorly controlled dyslipidemia.~18. Presence of a severe health problem, not being suitable for the study.~19. Pregnant or breastfeeding.~20. Inability to participate in the study (including psychiatric and psychosocial problems), as assessed by the investigators.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGLT2 inhibitor (Type: ACTIVE_COMPARATOR): N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.
- Sulfonylurea (Type: ACTIVE_COMPARATOR): N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Conservative Treatment of Acute Appendicitis in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 5-15 years old with a clinical diagnosis of appendicitis that prior to the trial would have been subjected to a surgical intervention~Exclusion Criteria:~* Suspicion of perforated appendicitis on the basis of generalized peritonitis~* An appendiceal mass, diagnosed either by palpation or with radiology

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Appendectomy (Type: ACTIVE_COMPARATOR): Standard surgical treatment, appendectomy
- Conservative, non-surgical treatment (Type: EXPERIMENTAL): Non-operative treatment with intravenous and oral antibiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men or women between the ages of 18 and 45 years old~Exclusion Criteria:~* History (including family history) or symptoms of, or risk factors for bleeding~* History (including family history) of or risk factors for a hypercoagulable or thrombotic condition~* Absolute/relative contraindication to anticoagulation or treatment with specific anticoagulants~* History of major surgery, severe trauma or bone fracture within 3 months prior to dosing; or planned surgery within 1 month after dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Module 1 (90 mg bolus) (Type: EXPERIMENTAL): 90 mg PRT064445 given as a single IV
- Module 1 (210 mg bolus) (Type: EXPERIMENTAL): 210 mg PRT064445 given as a single IV bolus
- Module 1 (420 mg bolus) (Type: EXPERIMENTAL): 420 mg PRT064445 given as a single IV bolus
- Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min (Type: EXPERIMENTAL): 600 mg PRT064445 given as follows: 420 mg IV over \~14 minutes (\~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes)
- Module 1 (420 mg bolus + 180 mg bolus) 30mg/min (Type: EXPERIMENTAL): 600 mg PRT064445 given as follows: up to 420 mg IV over \~14 minutes (\~30 mg/min), followed by a second bolus of 180 mg IV over \~6 minutes (\~30 mg/min), 45 minutes after completion of the bolus
- Module 1 (420 mg bolus + 480 mg infusion) 4mg/min (Type: EXPERIMENTAL): 900 mg PRT064445 given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes
- Module 1 Placebo (Type: PLACEBO_COMPARATOR): Placebo administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Dyslipidemic participants with Chronic Kidney Disease Stage 3~* For entry into the Treatment Phase (Visit 3), the participant satisfied the following laboratory criteria (measured at the Screening Visit\[s\]):~  * Estimated glomerular filtration rate between 30 and 59 mL/min/1.73 m2 (Chronic Kidney Disease Stage 3) by simplified 4 variable Modification of Diet in Renal Disease formula (this includes a 10 percent variation in the upper limit of estimated glomerular filtration rate that was allowed for the enrollment of participants to account for variability in the creatinine assay).~ * Fasting lipid results following greater than or equal to 12-hour fasting period:~* Triglycerides level greater than or equal to 150 mg/dL,~* High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and~* Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL Exclusion Criteria~* Participants with certain chronic or unstable medical conditions.~* Participants with unstable dose of medications or receiving coumarin anticoagulants, systemic cyclosporine, or certain other medications.~* Pregnant or lactating women, or women intending to become pregnant.~* Participants with diabetes mellitus that is poorly controlled.~* Participants of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-335 plus rosuvastatin (Type: EXPERIMENTAL): ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
- Rosuvastatin (Type: ACTIVE_COMPARATOR): Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Gestational age of at least 16 weeks.~* P. falciparum parasitaemia of any density with or without symptoms.~* Informed consent.~* No known adverse reaction to any of the study drugs.~* Residence in the study area.~Exclusion Criteria:~* Past obstetric and medical history that might adversely affect the interpretation of outcomes such as repeated stillbirths and eclampsia.~* History of severe adverse drug reactions to co-trimoxazole in the past.~* Haemoglobin concentration below 5.0 g/dl.~* Severe malaria.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of binge-eating disorder~* 3 or more binge days per week in the 2 weeks prior to baseline~* Obese (body mass index \>=30 and \<=50 kilograms per square meter)~* Uncomplicated/controlled Type II diabetes or hypertension are acceptable~* In generally good health~* If female capable of having children, using acceptable method of birth control~Exclusion Criteria:~* No current or past history of schizophrenia, other psychotic disorder, or bipolar disorder~* Significant depression that requires treatment with medication or therapy~* At risk to self or others~* No current or recent (within 3 months) diagnosis of abusing drugs or alcohol~* Initiation of formal psychiatric therapy in past 6 months for binge-eating disorder or any other psychiatric disorder~* Pregnant or breast-feeding~* No clinically significant medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18~* Eligible and elect to undergo robotic prostatectomy surgery @ OhioHealth Dublin Methodist Hospital~Exclusion Criteria:~* Age \< 18~* Emergency surgery~* Ascites~* BMI\>44 or \<18

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AirSeal System (Type: ACTIVE_COMPARATOR): This group receives the AirSeal System for intraoperative insufflation.
- Standard Endopath (Type: ACTIVE_COMPARATOR): This group receives the Standard Endopath Trocar for intraoperative insufflation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of I-gel to the Laryngeal Mask Airway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subjects will be adult surgical candidates aged 18-80, ASA I-II, Mallampati I or II, presenting for elective surgery who require general anesthesia in whom tracheal intubation is not necessary.~2. Both male and female patients will be included.~Exclusion Criteria:~Patients will be excluded from the study if they present as Mallampati III or IV, ASA III-V or emergency status. Additionally, they will be excluded if they meet one of the contraindication criteria of the LMA including:~1. obesity, (BMI \> 35 kg/m2)~2. pregnancy~3. history of gastric regurgitation, heart burn, ileus or full stomach~4. history of low pulmonary compliance or high pulmonary resistance~5. known history of difficult endotracheal intubation or signs suggesting the possibility of difficult intubation~6. pharyngeal pathology~7. upper airway obstruction due to laryngeal pathology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- i-gel-SGA (Type: EXPERIMENTAL): Patients who received i-gel supraglottic device (i-gel airway) for intubation
- LMA-Unique (Type: ACTIVE_COMPARATOR): Patients who received the Laryngeal Mask Airway-Unique (uLMA) for intubation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Completed 24 weeks of study drug treatment and study participation in either pivotal study, MVT-601-3001 or MVT-601-3002~Key Exclusion Criteria:~1. Has undergone myomectomy, ultrasound-guided laparoscopic radiofrequency ablation, or any other surgical procedure for fibroids, uterine artery embolization, magnetic resonance-guided focused ultrasound for fibroids, or endometrial ablation for abnormal uterine bleeding at any time during the pivotal study (MVT-601-3001 or MVT-601-3002)~2. Met a withdrawal criterion in the pivotal study (MVT-601-3001 or MVT-601-3002).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA for 28 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete